Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Revenue projections:

Revenue projections for VRTX
Revenue projections for VRTX

Investors may react cautiously to news that Vertex Pharmaceuticals Incorporated's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 2.901000
forwardPE 19.951284
debtToEquity 10.908000
earningsGrowth 0.329000
revenueGrowth 0.095000
grossMargins 0.536650
operatingMargins 0.396020
trailingEps 15.320000
forwardEps 21.808120

With a current ratio of 2.901, VRTX has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that VRTX is in a strong position to meet its immediate financial obligations without difficulty.
Vertex Pharmaceuticals Incorporated's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
VRTX's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making VRTX a financially resilient company with lower exposure to debt-related pressures.
VRTX's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
With a forward EPS greater than its trailing EPS, VRTX is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for VRTX
Price projections for VRTX

VRTX's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for VRTX
Insider Transactions for VRTX


31 sales transactions of VRTX were conducted, with market price at 467.8558054277974.Vertex Pharmaceuticals Incorporated saw 1 transactions to buy shares, with a market price of 385.6499938964844.More sells than buys at Vertex Pharmaceuticals Incorporated's current price levels suggest a potential downside. If this selling trend persists, it could trigger further price declines, as increased selling often reflects investor pessimism about the stock's future prospects.

Recommendation changes over time:

Recommendations trend for VRTX
Recommendations trend for VRTX


Analysts are favoring VRTX with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider VRTX as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.